Stifel raised its price target for NewLink Genetics (NASDAQ:NLNK) to $29 from $14 after the company on the weekend updated Phase 2 data in patients with advanced melanoma. The stock closed at $17.67 on Sept. 8.Read More
H.C. Wainwright downgraded Agenus (NASDAQ:AGEN) to “neutral” from “buy” and slashed its price target to $5 from $10. The stock closed at $4.33 on Thursday.
Analyst Swayampakula Ramakanth writes that during Agenus’ third quarter earnings, the company announced development of CTLA-4 and PD-1 checkpoint modulators (CPMs) as the focus of the company’s cancer immunotherapy pipeline.Read More